Clinical study of sintilimab and R-MT regimen in the treatment of primary central nervous system diffuse large B-cell lymphoma
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Lenalidomide (Primary) ; Methotrexate (Primary) ; Rituximab (Primary) ; Sintilimab (Primary) ; Temozolomide (Primary)
- Indications CNS cancer; Diffuse large B cell lymphoma; Eye neoplasms
- Focus Biomarker; Therapeutic Use
Most Recent Events
- 12 Dec 2023 Primary endpoint has been met. (ORR), as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Status has been changed to completed, as per Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition